4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

F. Cardoso; E. Senkus; A. Costa; E. Papadopoulos; M. Aapro; F. André; N. Harbeck; B. Aguilar Lopez; C. H. Barrios; J. Bergh; L. Biganzoli; C. B. Boers-Doets; M. J. Cardoso; L. A. Carey; J. Cortés; G. Curigliano; V. Dié Ras; N. S. El Saghir; A. Eniu; L. Fallowfield; P. A. Francis; K. Gelmon; S. R.D. Johnston; B. Kaufman; S. Koppikar; I. E. Krop; M. Mayer; G. Nakigudde; B. V. Offersen; S. Ohno; O. Pagani; S. Paluch-Shimon; F. Penault-Llorca; A. Prat; H. S. Rugo; G. W. Sledge; D. Spence; C. Thomssen; D. A. Vorobiof; B. Xu; L. Norton; E. P. Winer

doi:10.1093/annonc/mdy192

4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

F. Cardoso, E. Senkus, A. Costa, E. Papadopoulos, M. Aapro, F. André, N. Harbeck, B. Aguilar Lopez, C. H. Barrios, J. Bergh, L. Biganzoli, C. B. Boers-Doets, M. J. Cardoso, L. A. Carey, J. Cortés, G. Curigliano, V. Dié Ras, N. S. El Saghir, A. Eniu, L. FallowfieldP. A. Francis, K. Gelmon, S. R.D. Johnston, B. Kaufman, S. Koppikar, I. E. Krop, M. Mayer, G. Nakigudde, B. V. Offersen, S. Ohno, O. Pagani, S. Paluch-Shimon, F. Penault-Llorca, A. Prat, H. S. Rugo, G. W. Sledge, D. Spence, C. Thomssen, D. A. Vorobiof, B. Xu, L. Norton, E. P. Winer

NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Research output: Contribution to journal › Article › peer-review

905 Citations (Scopus)

Abstract

Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8].

Original language	English
Pages (from-to)	1634-1657
Number of pages	24
Journal	Annals of Oncology
Volume	29
Issue number	8
DOIs	https://doi.org/10.1093/annonc/mdy192
Publication status	Published - 1 Jan 2018

Keywords

ABC
Advanced
Breast cancer
ESO-ESMO
Guidelines
Metastatic

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdy192

Cite this

Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., Biganzoli, L., Boers-Doets, C. B., Cardoso, M. J., Carey, L. A., Cortés, J., Curigliano, G., Dié Ras, V., El Saghir, N. S., Eniu, A., ... Winer, E. P. (2018). 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Annals of Oncology, 29(8), 1634-1657. https://doi.org/10.1093/annonc/mdy192

@article{2d44225ef5484485bd763fdf813b9f10,

title = "4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)",

abstract = "Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8].",

keywords = "ABC, Advanced, Breast cancer, ESO-ESMO, Guidelines, Metastatic",

author = "F. Cardoso and E. Senkus and A. Costa and E. Papadopoulos and M. Aapro and F. Andr{\'e} and N. Harbeck and {Aguilar Lopez}, B. and Barrios, {C. H.} and J. Bergh and L. Biganzoli and Boers-Doets, {C. B.} and Cardoso, {M. J.} and Carey, {L. A.} and J. Cort{\'e}s and G. Curigliano and {Di{\'e} Ras}, V. and {El Saghir}, {N. S.} and A. Eniu and L. Fallowfield and Francis, {P. A.} and K. Gelmon and Johnston, {S. R.D.} and B. Kaufman and S. Koppikar and Krop, {I. E.} and M. Mayer and G. Nakigudde and Offersen, {B. V.} and S. Ohno and O. Pagani and S. Paluch-Shimon and F. Penault-Llorca and A. Prat and Rugo, {H. S.} and Sledge, {G. W.} and D. Spence and C. Thomssen and Vorobiof, {D. A.} and B. Xu and L. Norton and Winer, {E. P.}",

year = "2018",

month = jan,

day = "1",

doi = "10.1093/annonc/mdy192",

language = "English",

volume = "29",

pages = "1634--1657",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "European Society for Medical Oncology | Elsevier",

number = "8",

}

Cardoso, F, Senkus, E, Costa, A, Papadopoulos, E, Aapro, M, André, F, Harbeck, N, Aguilar Lopez, B, Barrios, CH, Bergh, J, Biganzoli, L, Boers-Doets, CB, Cardoso, MJ, Carey, LA, Cortés, J, Curigliano, G, Dié Ras, V, El Saghir, NS, Eniu, A, Fallowfield, L, Francis, PA, Gelmon, K, Johnston, SRD, Kaufman, B, Koppikar, S, Krop, IE, Mayer, M, Nakigudde, G, Offersen, BV, Ohno, S, Pagani, O, Paluch-Shimon, S, Penault-Llorca, F, Prat, A, Rugo, HS, Sledge, GW, Spence, D, Thomssen, C, Vorobiof, DA, Xu, B, Norton, L & Winer, EP 2018, '4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)', Annals of Oncology, vol. 29, no. 8, pp. 1634-1657. https://doi.org/10.1093/annonc/mdy192

TY - JOUR

T1 - 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

AU - Cardoso, F.

AU - Senkus, E.

AU - Costa, A.

AU - Papadopoulos, E.

AU - Aapro, M.

AU - André, F.

AU - Harbeck, N.

AU - Aguilar Lopez, B.

AU - Barrios, C. H.

AU - Bergh, J.

AU - Biganzoli, L.

AU - Boers-Doets, C. B.

AU - Cardoso, M. J.

AU - Carey, L. A.

AU - Cortés, J.

AU - Curigliano, G.

AU - Dié Ras, V.

AU - El Saghir, N. S.

AU - Eniu, A.

AU - Fallowfield, L.

AU - Francis, P. A.

AU - Gelmon, K.

AU - Johnston, S. R.D.

AU - Kaufman, B.

AU - Koppikar, S.

AU - Krop, I. E.

AU - Mayer, M.

AU - Nakigudde, G.

AU - Offersen, B. V.

AU - Ohno, S.

AU - Pagani, O.

AU - Paluch-Shimon, S.

AU - Penault-Llorca, F.

AU - Prat, A.

AU - Rugo, H. S.

AU - Sledge, G. W.

AU - Spence, D.

AU - Thomssen, C.

AU - Vorobiof, D. A.

AU - Xu, B.

AU - Norton, L.

AU - Winer, E. P.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8].

AB - Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8].

KW - ABC

KW - Advanced

KW - Breast cancer

KW - ESO-ESMO

KW - Guidelines

KW - Metastatic

UR - http://www.scopus.com/inward/record.url?scp=85053909898&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy192

DO - 10.1093/annonc/mdy192

M3 - Article

C2 - 30032243

AN - SCOPUS:85053909898

SN - 0923-7534

VL - 29

SP - 1634

EP - 1657

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -

4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this